Schrödinger Co-Founds Tectora Therapeutics with $55M Series A to Advance Immunology and Inflammation Programs
核心洞察
Schrödinger (搜索) co-founded Tectora Therapeutics (搜索) with New Enterprise Associates (搜索) and RA Capital Management (搜索) to develop innovative therapies for immunology and inflammation.
Tectora closed a $55 million Series A investment from NEA and RA Capital, with Schrödinger (搜索) contributing two early-stage small molecule programs (SDGR-4594 (搜索) and SDGR-8139 (搜索)).
Schrödinger (搜索) received an equity stake in Tectora and is eligible for future milestones and royalties, while Tectora will leverage Schrödinger's computational platform and drug discovery experts.
Schrödinger (搜索), Inc. (Nasdaq: SDGR) announced the formation of Tectora Therapeutics (搜索), a new biotechnology company it co-founded with New Enterprise Associates (搜索) (NEA) and RA Capital Management (搜索), focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million Series A investment from NEA and RA Capital.
In connection with the transaction, Schrödinger (搜索) contributed two early-stage small molecule programs, SDGR-4594 (搜索) and SDGR-8139 (搜索), and in exchange received an equity stake in Tectora. Schrödinger is also eligible to receive future milestones and royalties. Tectora will partner with Schrödinger's drug discovery experts and leverage Schrödinger's computational platform at scale to further advance these programs to clinical candidates.
"Schrödinger (搜索) has a track record of creating and enabling programs for licensing to pharma companies or joining forces with venture funds to build successful biotechnology companies such as Nimbus, Morphic, Structure and Ajax. These partnerships have collectively generated over $750 million in proceeds to Schrödinger," said Karen Akinsanya, Ph.D., President, Therapeutics R&D, and Chief Strategy Officer, Partnerships, at Schrödinger. "We co-founded Tectora with NEA and RA Capital to pair our breakthrough science with the dedicated capital and industry expertise needed to rapidly advance these programs to patients."
"As early-stage company builders we look for opportunities where exceptional science is paired with a motivated entrepreneurial team," said J.C. Lopez, Principal, New Enterprise Associates (搜索). "We believe the Tectora team, paired with Schrödinger (搜索)'s internal drug discovery team and industry-leading computational platform, will be able to successfully advance programs against historically challenging immunology and inflammation targets."
"We were drawn to the opportunity to leverage Schrödinger (搜索)'s drug discovery expertise and capabilities to develop therapeutics against high-value, validated targets," said Jenna Hebert, Ph.D., Investment Director, RA Capital Management (搜索). "Immunology and inflammation remain areas of immense unmet patient need, and we are excited to co-found Tectora to advance these high-potential programs through preclinical development and into the clinic."
Tectora's Focus on Oral Medicines
Tectora Therapeutics (搜索) is a privately held biotechnology company developing differentiated oral medicines for immune-mediated diseases. The company is focused on translating clinically validated biology into convenient oral medicines for patients. By partnering with Schrödinger (搜索), Tectora leverages advanced computational tools, drug discovery expertise, and preclinical capabilities to advance its initial programs. Tectora aims to build a broad pipeline of medicines for patients with significant unmet need.
Schrödinger's Computational Platform
Schrödinger (搜索) is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs.
Investor Background
New Enterprise Associates (搜索), Inc. (NEA) is a global venture capital firm founded in 1977 with more than $35 billion in assets under management as of December 31, 2025. The firm invests in technology and healthcare companies at all stages of a company's lifecycle, from seed stage through IPO, with a track record including more than 285 portfolio company public listings and more than 510 mergers and acquisitions.
RA Capital Management (搜索), founded in 2004, is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital has over 250 employees and $16 billion in assets under management as of June 30, 2026. Its knowledge engine is guided by TechAtlas, its science-first internal research division, while Raven, its healthcare incubator, offers entrepreneurs a comprehensive business-building platform for biomedical innovation.